To find a new and effective anticancer drug target

Cancer is a heterogeneous disease, and signaling pathways plays an important role in the occurrence and progress of cancer. According to research through recombinant horse proteins, different gene mutations can cause different signal pathway abnormalities, resulting in the performance of different clinical subtypes. Different subtypes of various anti-cancer drug reactivity will be quite different. Complex signaling pathways affect the survival of cancer patients rate and prognosis. It is a difficult problem to find a new and effective anticancer drug target to regulate the corresponding signal pathway.

Ras gene is a kind of oncogene, including K-ras, H-ras and N-ras. They can promote cell proliferation and growth in normal cells. When it shows mutation activation, Ras signaling pathway promotes cell proliferation and then malignant transformation of cells happens. In February, the electronic edition of Cell published an article by Tim wang from the University of Cambridge, Massachusetts. Under the mentoring guidance of Whitehead Institute and the Cambridge broad Institute, the researchers conducted gene sequencing on 14 acute lymphatic Cell leukemia patients and compared the main gene map and the known genomic data and found that the genotype of cancer patients will be divided into different subtypes, contributing to the development of new treatment and application.

This article tittled Major Gene Analysis Reveals the Roles of Oncogene Ras and Lethal Interactions in Gene Network Synthesis focuses on the role of genes and proteins in Ras signaling pathways in the treatment of acute lymphoblastic leukemia and other malignant diseases. The study found that, once Ras protein occurs, the disease will develop and drug therapy can be said to have been "powerless". Only from the gene level inhibition of Ras signaling pathway can effectively prevent the occurrence of malignant tumors.

With the development of genetic engineering technology, by knocking out 18,000 protein-coding genes one by one in the human genome through CRISPR-based gene editing technology, we can find the regulatory role of the Ras signaling pathway genes so as to find new anti-cancer gene target and to promote individualized treatment of cancer. It is believed that in the near future, the target drug acting on the Ras signal pathway can be applied to the clinical treatment of malignant diseases. Flarebio offers suprior recombinant proteins such as recombinant ITGB5 at good prices.